InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: ku post# 279640

Sunday, 11/27/2016 12:23:08 PM

Sunday, November 27, 2016 12:23:08 PM

Post# of 346073
I can understand, but also try to give some benefit of the doubt to management due to resistance on many fronts over the years.

If Steve Worsley and Ramon Valencia and others all help in closing a deal ( a deal that may have already been started back in March 2014 ) over the next month or so, then great.

If no one can close a deal and this goes to a reverse split and THEN a deal closes.... I would not trust that "EVERYTHING" was done to get this back over a $1 before that time

If this does get back to close to $3+ in time and THEN reverse split STILL occurs.... "BEFORE" even bigger news appears then I still may not trust how things went (but at least they would have got it back to $3+ before that time...)

We certainly don't see all the cards behind the scenes, but Peregrine Pharmaceuticals may not also see them either.

I hope they go with making a few good deals vs trying to close a major deal with one BP (that may be concerned about 50% of the current shareholders that may be associated with another BP), because that single BP would have motives to try and steer PPHM into that reverse split.

Hopefully I am wrong and news can flow and we hit $3+ and NO NEED for that reverse split.

Of course for news to really flow, the PR must be written so all people understand... like those that buy marijuana stock that don't smoke marijuana will KNOW that next best stock is Immunotherapy stocks and the top one is PPHM, even those that don't follow Immunotherapy yet. Everyone knows someone that has/had cancer and Peregrine needs to hire a marketing writer or something because the only conclusion I draw from their last PR's is they are not ready for the price to run higher...yet.

The PR must explain Immunotherapy, the basics and written so the puzzle is clear in 3 paragraphs on why ALL will need PS Targeting.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News